-+ 0.00%
-+ 0.00%
-+ 0.00%

Santen says China CDE accepts NDA for STN1012700 low-dose atropine myopia eye drop

PUBT·09/14/2026 06:34:30
Listen to the news
Santen says China CDE accepts NDA for STN1012700 low-dose atropine myopia eye drop
  • China’s CDE accepted Santen’s NDA for STN1012700, an atropine sulfate 0.025% eye drop to slow myopia progression.
  • Product targets suppression of ocular axial elongation; preservative-free, unit-dose formulation aimed at long-term pediatric use.
  • Japan launch occurred in April 2025 under the RYJUSEA Mini ophthalmic solution 0.025% brand.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Santen Pharmaceutical Co. Ltd. published the original content used to generate this news brief on September 14, 2026, and is solely responsible for the information contained therein.